 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | Treatment Action Group |
| Street 1: | 261 5th Ave, Suite 2110 |
| Street 2: | |
| City: | New York |
| Province: | NY |
| Post Code: | 10016 |
| Country: | United States of America |
| Phone: | 2122537922 |
| Email: | tag@treatmentactiongroup.org |
| Web Site: | http://www.treatmentactiongroup.org |
|
|
||||||||||||||||||||||||||||
General Information | |
| Organization Type - Primary: | Non-Governmental Organization |
| Organization Type - Secondary: | Community-Based Organization (CBO) |
| Is your organization legally registered in your country: | Yes |
| Organization Reach: | International |
| Organization Description: | |
| TAG is a community-based HIV/AIDS research and treatment advocacy organization with focus areas in basic science, immunology, antiretroviral drug development, community education and mobilization, and TB/HIV. | |
| Total number of staff in your organization: | 6 - 10 |
| Number of full-time staff who are directly involved with TB: | 1 - 5 |
| Number of part-time staff who are directly involved with TB: | 1 - 5 |
| Number of volunteers who are directly involved with TB: | 0 |
| What is your organization's annual budget (USD) dedicated to TB? | $500,001-$1 MIL |
| How did you hear about the Stop TB Partnership: | Other partners |
| Why do you wish join the Stop TB Partnership: | Involvement in Stop TB Working Groups |
| Are you a member of a Stop TB national partnership: | No |
| Are you in contact with your national TB programme: | Yes |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| Through supporting the CDC's TB Research Trial Consortium, participating in national policy development through the Advisory Council on the Elimination of TB, and increasing support for TB programs and research within the US national budget. | |
Geographical Reach | |
| Which country is your headquarters located in: | United States of America |
| Which WHO region is the main focus of your work: | American |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
United States of America |
Specializations | |
|
Advocacy, communication and social mobilization |
Specializations in Countries | |
| Advocacy, communication and social mobilization | United States of America |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
Drug-Resistant TB: Monitoring the scale up of diagnostics and treatment for drug-resistant TB and assessing the contributions of national leadership and grading the performance of Global Laboratory Initiative, the Green Light Committee, and the Global Drugs Facilities towards the scale up of DR-TB treatment. TB-HIV: Advocacy for the scale up for of TB/HIV collaborative services. On the core of the TB/HIV Working Group. Ensuring that new tools are developed are effective in addressing TB in people with HIV. New Diagnostics: Monitoring the pipeline of new TB diagnostics and advocating for increased research and a comprehensive TB diagnostics portfolio. Tracking resources available for R&D for TB diagnostics compared to the targets set by the Global Plan to Stop TB 2011-2015. New TB Drugs: Monitoring the pipeline of new TB drugs and advocating for increased research and a comprehensive TB drugs portfolio. Tracking resources available for R&D for TB drugs compared to the targets set by the Global Plan to Stop TB 2011-2015. Participating on the Stakeholders Association of the New TB Drugs Working Group New TB Vaccines: Monitoring the pipeline of new TB vaccines and advocating for increased research and a comprehensive TB vaccines portfolio. Tracking resources available for R&D for TB vaccines compared to the targets set by the Global Plan to Stop TB 2011-2015. Fundamental Research: Monitoring fundamental TB research and advocating for increased research and a comprehensive TB fundamental research portfolio. Tracking resources available for TB fundamental research compared to the targets set by the Global Plan to Stop TB 2011-2015. Operational Research: Monitoring the TB operational research and advocating for increased research that will improve programmatic implementation. Tracking resources available for TB operational research compared to the targets set by the Global Plan to Stop TB 2011-2015. |
|
Declaration | |
| Declaration of interests: N/A. | |
| Application date: | |
| Last updated: | May 10, 2012 |